![]() SOUTH SAN FRANCISCO, Calif., Ma/PRNewswire/ - Portola Pharmaceuticals, Inc.(®) (Nasdaq: PTLA) today announced the presentation of new data demonstrating that using Andexxa(®) to treat patients with intracranial hemorrhage (ICH) associated with the oral Factor Xa inhibitors apixaban or rivaroxaban is projected to provide a net reduction in costs to an acute care hospital.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |